Treatments for Obsessive-Compulsive Disorder

2015 ◽  
Author(s):  
Darin D. Dougherty ◽  
Scott L. Rauch ◽  
Michael A. Jenike
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Behavior Therapy ◽  
First Line ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
First Line Therapy ◽  
Line Therapy ◽  
Augmentation Strategies ◽  
Overwhelming Evidence ◽  
Limited Support

There is overwhelming evidence of the most rigorous type supporting the efficacy of serotonin reuptake inhibitors (SRIs) in the treatment of obsessive-compulsive disorder (OCD). Along with SRIs, behavior therapy must be considered a viable first-line therapy. The best available data suggest that behavior therapy, and perhaps cognitive therapy, is at least as effective as medication in some instances and may be superior with respect to risks, costs, and enduring benefits. A variety of second-line medication treatments for OCD have been studied in a controlled or systematic fashion. Augmentation of SRIs with antipsychotics, buspirone, or clonazepam is provisionally recommended based on the available data. Other monotherapies and augmentation strategies find very limited support at present.

Pharmacological Treatments for Obsessive-Compulsive Disorder

2007 ◽  
pp. 447-474 ◽  
Author(s):  
Darin D. Dougherty ◽  
Scott L. Rauch ◽  
Michael A. Jenike
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Behavior Therapy ◽  
Serotonin Reuptake Inhibitors ◽  
Second Line ◽  
Obsessive Compulsive ◽  
Tic Disorder ◽  
Compulsive Disorder ◽  
First Line Therapy ◽  
Augmentation Strategies ◽  
Overwhelming Evidence

There is overwhelming evidence of the most rigorous type supporting the efficacy of serotonin reuptake inhibitors (SRIs) in the treatment of obsessive-compulsive disorder (OCD). Along with SRIs, behavior therapy must be considered a viable first-line therapy. The best available data suggest that behavior therapy, and perhaps cognitive therapy, is at least as effective as medication in some instances, and may be superior with respect to risks, costs, and enduring benefits. A variety of second-line medication treatments for OCD have been studied in a controlled or systematic fashion. Augmentation of SRIs with clonazepam or buspirone, and with high-potency neuroleptics in cases of a comorbid tic disorder are all provisionally recommended based on the marginal available data. Other augmentation strategies find very limited support at present.

Selecting a Serotonin Reuptake Inhibitor for Obsessive-Compulsive Disorder

CNS Spectrums ◽  
1996 ◽  
Vol 1 (2) ◽  
pp. 32-38 ◽  
Author(s):  
Alison Kelly
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Common Condition ◽  
First Line ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Compulsive Disorder ◽  
Treatment Comparison ◽  
First Line Therapy ◽  
Line Therapy ◽  
High Doses

AbstractAlthough considered rare and intractable until relatively recently, obsessive-compulsive disorder (OCD) is now recognized as a common condition that can be treated. Clomipramine initially dominated the treatment of OCD, but the introduction of the selective serotonin reup-take inhibitors (SSRIs) now allows OCD to be treated without the unpleasant adverse effects associated with the high doses of clomipramine necessary in OCD. Double-blind, placebo-controlled, and active treatment comparison trials showing the efficacy of fluvoxamine and fluoxetine in particular now provide good reasons to consider SSRIs as first-line therapy for OCD.

scholarly journals Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Domenico De Berardis ◽  
Nicola Serroni ◽  
Stefano Marini ◽  
Giovanni Martinotti ◽  
Francesca Ferri ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Chronic Condition ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Atypical Antipsychotics ◽  
Young Female ◽  
Treatment Resistant ◽  
First Line ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Augmentation Strategies

Obsessive-compulsive disorder (OCD) is a chronic condition characterized by obsessions or compulsions that cause distress or interfere with functioning. Selective serotonin reuptake inhibitors are the first-line strategy in the treatment of OCD, but approximately 40% to 60% of patients with OCD fail to respond to them. Several augmentation strategies have been proposed, including the use of atypical antipsychotics and antidepressant combinations. In the present paper we describe the case of a young female patient suffering from severe treatment-resistant OCD who remitted as a result of agomelatine augmentation of escitalopram therapy.

Pharmacological Treatments for Obsessive Compulsive Disorder

2012 ◽  
Author(s):  
Darin D. Dougherty ◽  
Scott L. Rauch ◽  
Michael A. Jenike
Keyword(s):  
Behavior Therapy ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Study Behavior ◽  
Rigorous Research ◽  
Overwhelming Evidence ◽  
Limited Support ◽  
Emerging Treatments ◽  
New Compounds ◽  
Opioid Systems

Progress in treating OCD has accelerated in recent years. Effective first-line treatments include behavior therapy and medications, with overwhelming evidence supporting the efficacy of serotonergic reuptake inhibitors (SRIs). Second-line medication treatments for OCD include augmentation of SRIs with neuroleptics, clonazepam, or buspirone, with limited support for other strategies at present. Alternative monotherapies (e.g., buspirone, clonazepam, phenelzine) have more limited supporting data and require further study. Behavior therapy, and perhaps cognitive therapy, is as effective as medication and may be superior in risks, costs, and enduring benefits. Future rigorous research is needed to determine which patients respond preferentially to which medications, at what dose, and after what duration. Emerging treatments include new compounds acting via serotonergic, dopaminergic, glutamatergic, and opioid systems.

scholarly journals Pharmacotherapy for obsessive—compulsive disorder

2011 ◽  
Vol 17 (6) ◽  
pp. 419-434 ◽  
Author(s):  
Naomi Fineberg ◽  
Angus Brown
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Pharmacological Treatment ◽  
Special Populations ◽  
Evidence Based ◽  
First Line ◽  
Obsessive Compulsive ◽  
Evidence Based Treatment ◽  
Compulsive Disorder ◽  
Augmentation Strategies ◽  
Treatment Refractory

SummaryWe present a narrative review of evidence-based treatment for obsessive–compulsive disorder (OCD), covering first-line pharmacological treatment, augmentation strategies, approaches for treatment-refractory OCD and the management of OCD in special populations (children and adolescents, pregnant and breast-feeding women, and elderly people).

scholarly journals Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Alexandre Vallée ◽  
Jean-Noël Vallée ◽  
Yves Lecarpentier
Keyword(s):  
Oxidative Stress ◽  
Obsessive Compulsive Disorder ◽  
Therapeutic Strategy ◽  
Behavioral Therapy ◽  
First Line ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
First Line Therapy ◽  
New Treatment ◽  
Gsk 3Β

AbstractObsessive–compulsive disorder (OCD) is a neuropsychiatric disorder characterized b–y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and the glutamatergic pathway play key roles in the causes of OCD. However, first-line therapies include cognitive–behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for a new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in OCD.

St. John's Wort:Clinical Status in Psychiatry

CNS Spectrums ◽  
2001 ◽  
Vol 6 (10) ◽  
pp. 835-840 ◽  
Author(s):  
Samantha E. Meltzer-Brody
Keyword(s):  
Perennial Herb ◽  
Antidepressant Effect ◽  
Generalized Anxiety ◽  
Depression And Anxiety ◽  
First Line ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Complementary And Alternative Therapies ◽  
First Line Therapy ◽  
Line Therapy

ABSTRACTDepression and anxiety are among the top 10 health problems for which complementary and alternative therapies (CATs) are most frequently used, and medicinal herbs are among the most popular of these treatments. St. Johns wort(Hypericum perforaturn) is a perennial herb that has become a widely used depression therapy. Extracts of hypericum have shown affinity for receptors within multiple neurochemical systems. The primary active substance responsible for the antidepressant effect is not well defined, but most work has concentrated specifically on the hypericin and hyperforin components. Although hypericum has demonstrated significant antidepressant and antianxiety effects in multiple studies, there are several recent studies that do not support the previous evidence. In all reported studies, hypericum extracts have been well tolerated. In addition, new psychiatric uses for hypericum in obsessive-compulsive disorder, generalized anxiety disorder, menopausal symptoms, and alcohol dependence have been reported. Because patients are choosing to pursue CAT as a first-line therapy, psychiatrists will need to have a better understanding of phytomedicines used for treating depression and anxiety, and thus be better prepared to serve as effective allies of their patients.

Sign in / Sign up

Export Citation Format

Share Document